The scale of the underlying data is itself noteworthy. The team conducted ancestry-specific meta-analyses of genome-wide association studies, or GWAS, in Europeans and East Asians separately, and then pooled the results in a joint trans-ancestry meta-analysis encompassing 16,030 bronchiectasis cases and 1,841,141 controls. This design matters because genetic architectures can differ subtly between populations, and combining ancestries increases both statistical power and the chances of detecting variants that are rare or population-specific. The ancestry-specific analyses identified five bronchiectasis lead loci in Europeans and one in East Asians, while the trans-ancestry analysis converged on five lead signals, the strongest of which was a variant known as rs28929474, annotated to the gene SERPINA1.

That top hit is biologically compelling. SERPINA1 encodes alpha-1 antitrypsin, a protease inhibitor whose deficiency is already a well-established cause of both emphysema and bronchiectasis. The fact that the strongest cross-ancestry signal lands squarely on this gene provides a satisfying validation of the study’s methodology: the analysis is not merely generating statistical noise but recovering biology that clinicians already recognize, while simultaneously extending it to new candidates. It also underscores the value of including diverse populations, since signals that might be diluted or absent in one ancestry can emerge clearly when data from multiple ancestries are integrated.

Identifying lead variants is only the first step in modern disease genetics, because a single genomic region can contain dozens of correlated variants that travel together through inheritance, a phenomenon known as linkage disequilibrium. To disentangle which variants are most likely to be the true causal drivers, the researchers performed statistical fine-mapping, a computational approach that weighs each candidate variant’s association strength and correlation structure to produce credible sets of plausible culprits. This procedure yielded two credible sets in the European analysis and three in the trans-ancestry analysis, narrowing the field of candidate causal variants considerably and providing a more precise starting point for functional follow-up.

Perhaps the most innovative layer of the study is its use of proteome-wide Mendelian randomization based on cis-protein quantitative trait loci, or cis-pQTLs. Mendelian randomization exploits naturally occurring genetic variants as instruments to test whether a causal relationship exists between an exposure, in this case the circulating level of a specific protein, and a disease outcome. Because genetic variants are randomly allocated at conception, this approach is largely immune to the confounding and reverse causation that plague observational epidemiology. By restricting instruments to variants near the gene encoding each protein, the researchers reduced the risk of pleiotropic artifacts. In the European data, this analysis, combined with colocalization tests that verify whether the same variant drives both protein levels and disease risk, prioritized AIF1 and WWP2 as candidate proteins for bronchiectasis. The corresponding East Asian analyses nominated HSPA1A and DXO.

These protein candidates span intriguing biology. AIF1, also known as allograft inflammatory factor 1, is involved in immune cell activation and inflammatory signaling, processes central to the chronic neutrophilic inflammation that characterizes bronchiectatic airways. WWP2 is an E3 ubiquitin ligase with roles in protein degradation and developmental signaling pathways, including those governing airway epithelial biology. HSPA1A encodes a heat shock protein that orchestrates cellular stress responses, while DXO participates in RNA processing and quality control. That different ancestries surfaced different candidate proteins is not necessarily a weakness of the study; rather, it may reflect genuine population-level differences in disease mechanisms, differing allele frequencies, or differences in the protein quantitative trait loci resources available for each group. Each candidate now represents a hypothesis that can be tested experimentally in cellular and animal models of airway disease.

The team also applied transcriptome-wide association studies, or TWAS, which ask whether genetically predicted expression of a gene in a specific tissue, here the lung, is associated with disease risk. Integrated with colocalization analysis to ensure the expression signal and the disease signal share the same underlying variant, the lung TWAS in Europeans prioritized CHP2 and FUBP1. CHP2 is a calcineurin homologous protein implicated in ion transport and cell proliferation pathways, while FUBP1 is a far upstream element binding protein that regulates transcription and, notably, has been linked to the expression of CFTR, the chloride channel whose mutations cause cystic fibrosis, itself the classic cause of bronchiectasis. This convergence of transcriptomic and proteomic evidence with known airway biology strengthens confidence that the prioritized targets are not statistical artifacts.

Beyond bronchiectasis in isolation, the study tackled a question of considerable clinical importance: why do bronchiectasis, COPD, asthma, and chronic bronchitis so frequently coexist in the same patients? The researchers quantified genetic correlation between bronchiectasis and these overlapping conditions, then performed cross-disease pleiotropic analyses to identify variants influencing more than one disease. This effort highlighted shared signals at SERPINA1, SMAD3, CFTR, and PHTF1, with additional support for SMAD3 coming from blood cis-eQTL-based Mendelian randomization and colocalization. SMAD3 is a central transducer of the TGF-beta signaling pathway, which regulates airway remodeling and fibrosis, and variants in SMAD3 are known to contribute to thoracic aortic disease with features overlapping connective tissue disorders. CFTR, as the cystic fibrosis gene, needs little introduction in this context, and its appearance among the shared signals reinforces the idea that impaired airway surface hydration and mucociliary clearance form a common mechanistic thread linking several chronic airway diseases.

The implications for drug development are tangible. Bronchiectasis currently lacks mechanism-informed therapies; management relies largely on airway clearance techniques, antibiotics for infective exacerbations, and treatment of underlying causes where they can be identified. By prioritizing proteins and genes whose genetically determined levels or expression influence disease risk, the study provides a shortlist of targets that pass some of the most stringent causal filters available in human genetics. Drugs aimed at proteins with human genetic evidence of disease relevance have historically shown higher success rates in clinical trials, and the multi-omics triangulation used here, spanning GWAS, fine-mapping, pQTL-based and eQTL-based Mendelian randomization, TWAS, and colocalization, is precisely the kind of evidence stack that pharmaceutical target selection increasingly demands.

Caveats remain, as they must in any genetics-first study. The analyses relied on summary-level data from previously generated studies, which means individual-level covariates, environmental exposures, and disease subphenotypes could not be modeled directly. Protein and expression quantitative trait loci resources differ in depth between ancestries, and the candidate targets nominated in East Asians and Europeans will require replication in additional cohorts and functional validation before they inform clinical practice. Nevertheless, the study marks a clear advance: it refines the cross-ancestry genetic architecture of bronchiectasis, confirms the centrality of protease-antiprotease imbalance through SERPINA1, and elevates a set of new molecular suspects, from AIF1 and WWP2 to CHP2 and FUBP1, into the spotlight of translational respiratory research. For a disease that has waited decades for precision-medicine attention, the genetic map is finally beginning to fill in.

Subject of Research: Cross-ancestry genetic architecture of bronchiectasis and multi-omics prioritization of candidate molecular drug targets

Article Title: Cross-ancestry bronchiectasis GWAS meta-analysis and multi-omics integration prioritize candidate molecular targets

Article References: Cross-ancestry bronchiectasis GWAS meta-analysis and multi-omics integration prioritize candidate molecular targets. (n.d.). https://doi.org/10.1186/s12967-026-09081-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09081-2

Keywords: bronchiectasis, GWAS, meta-analysis, Mendelian randomization, SERPINA1, pQTL, TWAS, colocalization, COPD, asthma, chronic bronchitis, drug targets

The research, led by Xin Gao and Xiaofeng Guo of Shanxi Provincial People’s Hospital together with Shaopeng Yang of Zhejiang Cancer Hospital and corresponding author Qi Zhang of Shandong Cancer Hospital and Institute, describes a protein-prioritised, colocalisation-informed framework for generating target-outcome safety hypotheses. Rather than waiting for post-marketing surveillance to reveal unexpected adverse events, the team asked whether human genetics could flag plausible safety concerns for eighteen genes that represent established or emerging inflammatory bowel disease therapeutic targets. The logic is elegant: if genetically lowered levels or expression of a drug’s target protein are associated with increased risk of a particular disease outcome in population data, then pharmacologically inhibiting that same target deserves closer scrutiny for a similar effect.

The technical architecture of the study is where much of its novelty lies. The authors assembled twenty-five sets of genetic instruments, drawn either from cis-protein quantitative trait loci, which are variants that alter circulating protein levels, or from cis-expression quantitative trait loci, which are variants that alter gene expression in blood. These proxies covered the eighteen therapeutic genes and were tested against seventy-six prespecified safety outcomes drawn from the FinnGen R13 biobank release, a Finnish resource combining genetic data with national health registry records covering conditions from autoimmune disease to venous thromboembolism. In total, 1,900 tasks were planned, of which 1,824 proved analysable, generating a matrix of target-outcome hypotheses that could be evaluated in a statistically disciplined way.

A key methodological challenge was sparsity. Stringent selection of cis-acting variants, which are preferred because they are less prone to confounding by distant genetic effects, often leaves only one or a handful of usable instruments per gene. Conventional Mendelian randomisation methods that require many variants are therefore poorly suited to this setting. The workflow adapted by combining single-variant or few-variant Wald ratios with inverse-variance-weighted estimates where multiple variants were available, and then applying rigorous false-discovery-rate control. A global Benjamini-Hochberg correction across all 1,824 estimates served as the primary filter, with secondary corrections applied within forty narrower outcome domains. This two-tier approach balanced statistical conservatism against the risk of missing genuine signals buried in the multiple-testing burden.

The criteria for advancing a hypothesis were deliberately strict. An estimate had to pass the global false-discovery threshold, point in a risk-increasing direction under simulated target lowering, and lie outside the major histocompatibility complex, a densely variable genomic region notorious for producing misleading associations because of its extreme linkage disequilibrium. Signals meeting these conditions entered an objective follow-up phase involving sensitivity analyses, instrument-centred colocalisation and variant-level annotation. Colocalisation is the critical step: it asks whether the genetic variant associated with the molecular proxy, such as a protein level, and the variant associated with the disease outcome are in fact the same causal variant, rather than two nearby variants inherited together. The team used Bayesian colocalisation methods in windows of plus or minus 250 kilobases centred on each instrument, requiring a posterior probability of a shared causal variant above 0.5.

From the initial screen, one hundred estimates passed global false-discovery control and twenty more met only the narrow-domain threshold, producing fifteen tasks representing thirteen distinct target-outcome pairs for follow-up. The final classification stratified hypotheses by molecular layer, distinguishing protein-level P1 and P2 categories from expression-level E1 and E2 categories depending on whether colocalisation support exceeded the threshold. This stratification matters because a hypothesis supported at the protein level, where the drug will actually act, carries different translational weight than one supported only at the messenger RNA level, where the relationship between expression and protein abundance is often imperfect.

Two protein-level P1 hypotheses emerged as the strongest safety signals. The first linked lower ITGB7, the integrin targeted by vedolizumab, a widely used gut-selective biologic, with increased risk of multiple sclerosis and demyelinating disease, showing an odds ratio of 2.35 with a global q-value of 0.003 and colocalisation support of 0.935. The second connected TNFRSF1A, a tumour necrosis factor receptor, with myocardial infarction, an association replicated across two independent proteomic resources, the UK Biobank Pharma Proteomics Project and deCODE, with odds ratios of 1.56 and 1.37 respectively, both driven by the same variant, rs4149584, which encodes the R92Q amino-acid substitution. The convergence of two independent protein datasets on the same variant and the same outcome lends considerable credibility to the signal.

At the expression level, two E1 hypotheses stood out, both involving psoriasis, an outcome of particular interest because psoriasis shares inflammatory pathways with inflammatory bowel disease and is itself a comorbidity of the condition. Reduced IL23A expression was associated with dramatically increased psoriasis risk, with an odds ratio of 4.13 and an exceptionally strong q-value of 7.47 times ten to the minus nine, while reduced TYK2 expression showed an odds ratio of 1.53 with a q-value of 1.10 times ten to the minus eleven and near-perfect colocalisation support of 0.984. These findings are biologically coherent: IL-23 and TYK2 are the molecular foundations of some of the most successful recent therapies in both psoriasis and inflammatory bowel disease, and the genetic data suggest that their pathways are deeply intertwined with psoriasis susceptibility in ways that clinicians managing patients with both conditions should note.

Not every candidate signal survived scrutiny, and the framework’s treatment of these failures is as informative as its successes. IL12B-psoriasis and TNFSF15-lower-extremity deep-vein thrombosis were classified as P2 hypotheses because colocalisation posterior probabilities fell below the 0.5 threshold, meaning the apparent associations could not be confidently attributed to a shared causal variant. This is precisely the kind of auditable, transparent triage that distinguishes a disciplined hypothesis-generation framework from a fishing expedition. Every step, from the 1,900 planned tasks through the 2,584 SNP-level rows, heterogeneity analyses, weighted-median estimates and leave-one-out sensitivity checks, is documented in supplementary workbooks, allowing independent researchers to audit the provenance of each conclusion.

The broader significance of this work lies in its positioning within the drug development pipeline. Safety signals that emerge from human genetics are not deterministic predictions; they are prioritised hypotheses that can direct mechanistic validation in experimental systems and targeted evaluation in clinical safety datasets before large populations are exposed. By stratifying evidence by molecular proxy type, enforcing locus specificity through colocalisation, and excluding the confounded major histocompatibility complex region, the framework produces a short, defensible list of target-outcome pairs that merit attention. For a therapeutic area where biologics have transformed patient outcomes but questions remain about long-term risks such as demyelination, infection and cardiovascular events, the ability to generate such lists computationally, using only publicly available summary-level data, represents a meaningful step toward safer and faster drug development. The authors’ emphasis on auditability and reproducibility suggests the framework could be extended to other disease areas, turning the human genome into a routine preclinical screening tool for pharmacovigilance.

Subject of Research: Genetic prediction of safety outcomes for inflammatory bowel disease therapeutic targets using Mendelian randomisation and colocalisation

Article Title: A protein-prioritised, colocalisation-informed genetic framework for safety hypothesis generation across inflammatory bowel disease therapeutic pathways

Article References: Gao, X., Guo, X., Yang, S., & Zhang, Q. (2026). A protein-prioritised, colocalisation-informed genetic framework for safety hypothesis generation across inflammatory bowel disease therapeutic pathways. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09068-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09068-z

Keywords: inflammatory bowel disease, Mendelian randomisation, colocalisation, pQTL, eQTL, drug safety, FinnGen, ITGB7, TNFRSF1A, TYK2, IL23A, pharmacovigilance

The study, published in Clinical Cancer Bulletin, employed a technique called proteome-wide Mendelian randomization, an epidemiological approach that exploits the random shuffling of genes at conception as a natural experiment. Because genetic variants are inherited independently of lifestyle and environmental factors, they can act as proxies, or instrumental variables, for protein levels in the blood. If people who carry variants that raise the circulating concentration of a particular protein also tend to develop lung squamous cell carcinoma more often, that suggests, though it does not prove, that the protein itself plays a causal role in the disease rather than merely riding along as a byproduct of tumor growth.

To build this genetic proxy system, the researchers drew on two of the largest protein-genetic datasets ever assembled: the UK Biobank Pharma Proteomics Project, which profiled 2,958 proteins in 54,306 participants using the Olink platform, and the deCODE Health study, which measured 4,906 proteins in 35,559 Icelanders using the SomaScan platform. After filtering out proteins lacking usable genetic instruments and excluding the notoriously tangled major histocompatibility complex region of chromosome 6, the team arrived at 1,046 proteins with shared protein quantitative trait loci, genetic variants reliably associated with plasma protein levels.

For the disease side of the equation, the investigators used summary statistics from the International Lung Cancer Consortium, comprising 3,275 lung squamous cell carcinoma cases and 15,038 controls of European ancestry, as their discovery dataset. They then replicated findings in the FinnGen study, with 1,510 cases and 314,193 controls, and in a separate genome-wide association study led by McKay and colleagues involving 7,426 cases and 55,627 controls. Applying a stringent Bonferroni correction for the more than a thousand proteins tested, the analysis converged on six proteins with statistically robust associations: HSPA1L, PCSK7, POLI, SPINK2, TCL1A, and VARS.

Three of these proteins emerged as protective. Higher genetically predicted levels of HSPA1L were associated with roughly half the odds of developing lung squamous cell carcinoma, with an odds ratio of 0.47. SPINK2 showed an odds ratio of 0.68, and VARS an even more striking 0.44, meaning each standard deviation increase in circulating levels of this valyl-tRNA synthetase corresponded to a 56 percent reduction in disease odds. In the combined meta-analysis across all three disease datasets, HSPA1L, SPINK2, and VARS remained consistently protective, with combined odds ratios of 0.51, 0.71, and 0.48 respectively and p-values approaching ten to the minus ten, a level of statistical significance rarely seen in observational cancer epidemiology.

The other three proteins pointed in the opposite direction. PCSK7, a proprotein convertase previously implicated in activating matrix metalloproteinases that facilitate tumor invasion, carried an odds ratio of 1.37. POLI, a low-fidelity DNA polymerase from the Y-family known to promote migration and invasion of lung cancer cells, showed the largest effect of all, with an odds ratio of 4.50. TCL1A, an oncogene that modulates the Akt/mTOR signaling pathway crucial for cell growth and survival, was associated with an odds ratio of 1.72. However, the replication picture for these three was more complicated: PCSK7 and TCL1A displayed significant heterogeneity across datasets, with combined estimates that no longer reached statistical significance, while POLI yielded wide confidence intervals spanning both harm and neutrality.

To guard against false positives arising from linkage disequilibrium, the phenomenon in which nearby genetic variants are inherited together and can masquerade as causal signals, the researchers deployed a battery of complementary analyses. Summary-data-based Mendelian randomization and the heterogeneity in dependent instruments, or HEIDI, test helped distinguish genuine protein-disease relationships from shared genetic architecture. Bayesian colocalization analysis assigned posterior probabilities to competing hypotheses about whether a protein association and a disease association in the same genomic region stem from one causal variant or two distinct ones. Notably, TCL1A passed both the HEIDI test and the colocalization threshold, with a posterior probability of hypothesis four, or PPH4, of 0.817, indicating that the same variant likely drives both TCL1A protein levels and lung squamous cell carcinoma risk. Sensitivity analyses including Cochran’s Q test for heterogeneity, the MR-Egger intercept test for horizontal pleiotropy, and MR-PRESSO outlier detection found no evidence that the primary associations were artifacts of pleiotropic genetic effects.

The biological stories behind these proteins add plausibility to the statistical findings. HSPA1L, a heat shock protein, has been shown in laboratory studies to enhance cancer stem cell-like properties by activating the insulin-like growth factor 1 receptor beta and regulating beta-catenin transcription, pathways central to tumor progression and therapy resistance. SPINK2, a serine protease inhibitor, is known to influence protease activity and intercellular communication within the tumor microenvironment, and elevated expression has been linked to poor prognosis in acute myeloid leukemia. VARS belongs to the aminoacyl-tRNA synthetase family, enzymes best known for charging transfer RNAs with amino acids during protein synthesis but increasingly recognized for non-canonical roles in signal transduction and cellular homeostasis that can promote cancer cell survival and proliferation.

The authors are candid about the limitations of their approach. The Mendelian randomization framework rests on the assumption that genetic instruments influence disease only through the protein of interest, and while the team excluded trans-associated loci, applied Steiger filtering, and ran extensive sensitivity analyses, horizontal pleiotropy can never be fully eliminated. Low colocalization posterior probabilities for some proteins, such as HSPA1L and VARS, may reflect limited statistical power rather than true absence of a shared causal variant, and interpreting these values requires caution. Moreover, all data came from individuals of European ancestry, raising questions about generalizability to other populations, and the reliance on pre-existing databases rather than real-world cohorts leaves room for population-specific biases.

Nevertheless, the study represents the first systematic proteome-wide causal scan for lung squamous cell carcinoma, a cancer that accounts for roughly 30 percent of non-small cell lung cancers and carries a five-year survival rate below 20 percent for advanced stages. Unlike previous Mendelian randomization efforts that focused on lung adenocarcinoma or on mitochondrial proteins, this work delivers a subtype-specific map of circulating proteins that may shape disease risk. If future functional studies and diverse real-world cohorts validate these findings, HSPA1L, SPINK2, and VARS could inspire protective therapeutic strategies, while PCSK7, POLI, and TCL1A, particularly TCL1A with its strong colocalization evidence, could become targets for drugs aimed at intercepting the disease before it takes hold. For a cancer with so few targeted options, six genetically anchored leads represent a meaningful step forward.

Subject of Research: Proteome-wide Mendelian randomization of plasma proteins as causal risk factors for lung squamous cell carcinoma

Article Title: Causal associations of plasma proteins with lung squamous cell carcinoma risk: a proteome-wide Mendelian randomization and colocalization analysis

Article References: Wang, Q., Xue, X., Ling, X., Lang, Y., Wang, S., & Liu, G. (2024). Causal associations of plasma proteins with lung squamous cell carcinoma risk: a proteome-wide Mendelian randomization and colocalization analysis. Clinical Cancer Bulletin, 3(1), Article 18. https://doi.org/10.1007/s44272-024-00024-w

Image Credits: AI Generated

DOI: 10.1007/s44272-024-00024-w

Keywords: lung squamous cell carcinoma, Mendelian randomization, proteomics, plasma proteins, colocalization analysis, HSPA1L, SPINK2, VARS, TCL1A, PCSK7, POLI, pQTL